Latest News

 

Spotlight

 

Technology

04-27-15 Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline
04-24-15 Zogenix Closes Sale of Zohydro(R) ER Business to Pernix
03-26-15 Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. Zogenix expects to begin a multi-dose clinical trial to provide steady-state pharmacokinetic and safety data in January 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.